SCHEMBL10140753

SCHEMBL10140753

CC(=O)c1n[nH]c(-c2ccc(Cl)nc2)c1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNIK Q9UKE5 1/20 0.39
ALDH1A1 P00352 2/20 0.36
CHEK1 O14757 1/20 0.36
PIK3CD O00329 1/20 0.36
NAPRT Q6XQN6 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35
DYRK1B Q9Y463 2/20 0.34
PRKAB2 O43741 1/20 0.34
PRKAG1 P54619 1/20 0.34
PRKAA2 P54646 1/20 0.34
PRKAA1 Q13131 1/20 0.34
PRKAG3 Q9UGI9 1/20 0.34
PRKAG2 Q9UGJ0 1/20 0.34
PRKAB1 Q9Y478 1/20 0.34
CYP2A6 P11509 1/20 0.34
PDK1 Q15118 1/20 0.34
PDK2 Q15119 1/20 0.34
PDK3 Q15120 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10172725 0.82 KDM4E (0.43) TNIKALDH1A1KDM4ENPC1RAB9A
SCHEMBL10140688 0.76 MAPT (0.41) ALDH1A1MEN1KMT2ADYRK1BKDM4E
SCHEMBL10140232 0.75 ADORA3 (0.43) ALDH1A1KDM4ENPC1RAB9A
SCHEMBL10140756 0.70 MEN1 (0.38) ALDH1A1PIK3CDNAPRTMEN1KMT2A
SCHEMBL10939257 0.69 KDM4E (0.47) ALDH1A1KDM4ENPC1RAB9A
SCHEMBL1742846 0.68 NAPRT (0.53) ALDH1A1PIK3CDNAPRTCYP2A6PDE10A
SCHEMBL31425530 0.64 PRKAG1 (0.43) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL29592337 0.63 NAPRT (0.67) ALDH1A1NAPRTMEN1KMT2AKCNQ3
Acetone SCHEMBL2165790 0.63 NAPRT (0.50) ALDH1A1NAPRTMEN1KMT2AATM
SCHEMBL213163 0.63 NAPRT (0.67) ALDH1A1NAPRTMEN1KMT2AKCNQ3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 TNIK 2238/4885ALDH1A1 1022/4885CHEK1 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.